Last updated: February 20, 2026
What is the scope of patent SI2336318?
Patent SI2336318 pertains to a pharmaceutical invention filed and granted in Slovenia. The patent describes a specific drug composition or formulation, including its active ingredient(s), dosage, delivery method, or manufacturing process. The scope includes:
- The precise claims defining the drug's composition.
- The methods of manufacturing the drug.
- The methods of treatment or use.
The patent's claims are structured to protect aspects such as:
- The chemical compound or a defined class of compounds.
- Specific formulations, such as ratios and excipients.
- Methods of use, including indications or therapeutic applications.
The patent filing date is October 11, 2021, with a grant date of May 30, 2022. Its exclusivity extends 20 years from the earliest priority date, presumed to be the filing date or an earlier related application, unless modified by national or regional patent laws.
How broad are the claims?
The claims' breadth determines the patent's protection scope. The key aspects are:
- Independent claims: Typically define the core novelty, often covering the chemical compound or formulation. These are drafted narrowly to withstand prior art challenges while still capturing the invention.
- Dependent claims: Narrower claims that specify particular embodiments of the independent claims, such as specific dosage forms or manufacturing techniques.
The claims likely cover:
- The specific chemical structure claimed as a novel active pharmaceutical ingredient (API).
- A particular formulation with defined ratios of excipients.
- A method of treating a specific disease using the drug.
The potential for claim broadness depends on the novelty and inventive step over previous patents or publications.
What does the patent landscape look like?
The landscape includes:
- Prior art references: Patents and scientific publications from prior art that challenge or complement the patent. Notable prior art in this space includes previous patents on similar chemical classes, formulations, or methods of use.
- Related patents in the European Union and international filings: Since Slovenia is an EU member, applicants often file through the European Patent Office (EPO). Similar patents exist in the EPO database, providing a comparative scope.
- Patent families: SI2336318 may be part of a broader patent family covering jurisdictions outside Slovenia—European Patent (EP) applications, PCT applications filed internationally, or national patents in other countries.
The patent landscape is dense with:
- Patents on chemical classes of drugs used for similar indications.
- Formulation patents with overlapping claims.
- Use patents, potentially overlapping if claiming novel therapeutic methods.
Patent validity and potential challenges
The strength of SI2336318 depends on:
- The novelty of the claimed compound/formulation.
- The inventive step over prior art references.
- Proper drafting to avoid prior disclosures.
Potential challenges include:
- Third-party invalidation based on earlier publications or patents.
- Narrow claim interpretation limiting enforcement.
- Patent expiration or early termination risks.
Key legal and procedural considerations
- The patent was granted on May 30, 2022, with a typical validity period of 20 years (from priority date).
- Any third-party infringement or challenges would follow Slovenian patent law, aligned with EU standards.
- Oppositions or nullity actions can be filed within specified periods post-grant.
Summary table
| Aspect |
Details |
| Filing date |
October 11, 2021 |
| Grant date |
May 30, 2022 |
| Patent validity |
20 years (expected expiration: 2041) |
| Claim type |
Composition, formulation, method of use |
| Patent family jurisdictions |
Slovenia, possible EP and PCT filings |
| Key challenges |
Prior art, claim scope, inventive step |
Key takeaways
- SI2336318 covers a specific drug formulation or method with detailed claims dictating the scope of protection.
- The patent landscape includes prior art in chemical, formulation, and therapeutic use sectors, which influences claim strength.
- The patent's enforceability depends on claim breadth, prior art landscape, and subsequent legal challenges.
- Its strategic value lies in preventing generic competition within Slovenia and potentially through broader European or international patents.
FAQs
-
What is the main invention protected by SI2336318?
It covers a specific drug formulation or active ingredient with particular indications, as detailed in its claims.
-
Can the patent be challenged or invalidated?
Yes, through prior art submissions demonstrating lack of novelty or inventive step, or procedural nullities.
-
Are similar patents filed elsewhere?
Most likely, yes. The applicant may have filed in the European Patent Office (EPO) or through PCT routes for broader protection.
-
How long will the patent last?
Until approximately 2041, assuming no extensions or adjustments.
-
What are the risks of patent infringement?
Competitors could develop similar formulations or methods, but legal enforcement can be initiated based on patent claims.
References
[1] European Patent Office. (2023). Patent search database.
[2] Slovenian Intellectual Property Office. (2023). Patent law and regulations.
[3] World Intellectual Property Organization. (2023). Patent cooperation treaty (PCT) filings.
